Several Life Science Tools and Services (LSTS) companies had a tough Q2, negatively impacted by a prolonged economic slowdown in China. They continued spending caution from biopharma clients in Europe and the United States. We expect this softness to persist for at least another one or two quarters, potentially reducing revenues and pressuring margins for a number of companies in the sub-industry. While the S&P Composite 1500 Life Sciences Tools & Services index underperformed the S&P Composite 1500 Index year-to-date, we think there are still good opportunities.
Life Science Tools and Services: Time to Be Selective Amid a Challenging H2 2023
Want to learn more? Download the Report.
Gain a comprehensive view of global themes, industries, and companies.
The Centers for Medicare & Medicaid Services (CMS) released a list...Read more